The Defense Advanced Research Projects Agency (DARPA), through its Microsystems Technology Office (MTO), has released Request for Information (RFI) DARPA-SN-26-66 focused on biomolecule purification technologies. The RFI seeks information on novel purification methods capable of enabling a universal platform for separating and recovering multiple large and complex molecules from complex biological feedstocks with high specificity, purity, and yield.
At a high level, DARPA is exploring whether next-generation purification technologies could fundamentally simplify downstream biomanufacturing processes by replacing today’s multi-step filtration and chromatography workflows with more flexible, tunable, and potentially single-step purification systems. According to the notice, these advances could reduce purification complexity, accelerate production timelines, and support new operational manufacturing capabilities.
The effort reflects growing federal interest in scalable and adaptable biomanufacturing systems capable of supporting a wide range of biologically produced molecules. DARPA specifically notes that many critical molecules are currently produced using genetically modified cells, but purification remains one of the most resource-intensive and inflexible portions of the manufacturing pipeline.
Importantly, DARPA states that responses to this RFI may inform the development of a future program. However, this notice is strictly for information gathering and program planning purposes and is not a formal solicitation for proposals.
Technical Focus Areas
Topic Area 1: Novel Purification Approaches
DARPA is seeking innovative purification technologies that could enable a single, tunable platform to separate and recover multiple large and complex molecules with high specificity and yield. Areas of interest include single-step purification methods, reusable purification systems, approaches that avoid affinity tags or affinity columns, and techniques capable of purifying de novo designed molecules.
The agency is particularly interested in technologies that could simplify today’s multi-step chromatography workflows and create more flexible downstream biomanufacturing capabilities.
Topic Area 2: Operational Impact and Future Capabilities
DARPA is also exploring how advanced purification methods could enable new operational and manufacturing capabilities. This includes small-scale or expeditionary manufacturing, distributed production environments, and broader applications for biologically produced molecules.
The agency is interested in understanding how flexible purification platforms could improve existing manufacturing systems and support future concepts of operation across defense and industrial biotechnology applications.
Key Dates and Submission Information
The response deadline is June 8, 2026 at 5:00PM Eastern Time.
Responses must be submitted electronically to [email protected] and are limited to four pages per topic area, excluding supplemental materials such as references and summary slides.
Strategic Implications for Biomanufacturing and National Security
This RFI highlights a growing federal interest in rethinking one of the most persistent constraints in modern biomanufacturing: downstream purification. While significant advances have been made in engineered biology and molecular production, purification workflows often remain slow, expensive, and highly specialized. DARPA’s interest in universal, tunable purification platforms signals an effort to close that gap and enable more agile manufacturing systems.
If successful, technologies emerging from this area could have implications far beyond traditional biopharmaceutical production. Flexible purification systems could support distributed manufacturing, rapid response bioproduction, expeditionary medical logistics, industrial biotechnology, and scalable production of next-generation synthetic biomolecules.
The emphasis on reusable, adaptable, and potentially single-step systems also aligns with broader defense priorities around operational resilience, supply chain flexibility, and scalable domestic biomanufacturing capacity.
If your company is considering applying for federal funding, your journey starts here. EverGlade is a national advisory firm helping innovators navigate the federal funding ecosystem. We support companies across the funding lifecycle, from early-stage strategy through proposal development, negotiations, and post-award execution, connecting breakthrough innovation with non-dilutive funding. We support programs across federal agencies including ARPA-H, BARDA, DARPA, DTRA, NIAID, CPE CBRND, DOE, and DFC, among others.
For additional information, schedule a free consultation with our team.
